Is combined L- and T-channel blockade better than L-channel blockade in therapy?
Theophile
T
Godfraind
D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000502:physiology; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D020746:Calcium Channels, L-Type / Q000502:physiology*; D020747:Calcium Channels, T-Type / Q000502:physiology*; D004095:Dihydropyridines / Q000494:pharmacology; D004357:Drug Synergism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D008638:Mesenteric Arteries / Q000187:drug effects / Q000502:physiology; D020748:Mibefradil / Q000494:pharmacology; D055806:Microvessels / Q000187:drug effects* / Q000502:physiology; D009543:Nifedipine / Q000494:pharmacology; D009596:Nitrophenols / Q000494:pharmacology; D051381:Rats; D014661:Vasoconstriction / Q000187:drug effects; D014700:Verapamil / Q000494:pharmacology
D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D020747:Calcium Channels, T-Type; D004095:Dihydropyridines; D009596:Nitrophenols; D020748:Mibefradil; D014700:Verapamil; D009543:Nifedipine